Gain the Knowledge You Need to Successfully Trade Futures Markets
Our Technical Analysis Guide will give you the insight into today’s fast-moving markets. It’s designed to give you a head start in learning the basics of various TA tools and techniques.
pixel

NASDAQ:MRNA - Moderna Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $162.44
  • Forecasted Upside: -17.89 %
  • Number of Analysts: 17
  • Breakdown:
  • 3 Sell Ratings
  • 6 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$197.84
▼ -3.75 (-1.86%)
1 month | 3 months | 12 months
Get New Moderna Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRNA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$162.44
▼ -17.89% Downside Potential
This price target is based on 17 analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is $162.44, with a high forecast of $231.00 and a low forecast of $80.00. The average price target represents a -17.89% upside from the last price of $197.84.
Learn How to Analyze Your Market and Trading Plan
Custom-design an options strategy to fit your market outlook. This guide goes beyond the basics to help you understand how to evaluate a strategy’s risk and reward. Start with your market outlook, then hone in on your strategy based on the risk you’re willing to take.
pixel

Hold

The current consensus among 17 contributing investment analysts is to hold stock in Moderna. This rating has held steady since July 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 1 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 2 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 6 hold ratings
  • 3 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 3 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 3 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 3 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2021Chardan CapitalBoost Price TargetBuy$182.00 ➝ $188.00Low
i
5/7/2021Morgan StanleyLower Price TargetEqual Weight$201.00 ➝ $190.00Low
i
5/7/2021BarclaysBoost Price TargetOverweight$178.00 ➝ $194.00Low
i
5/7/2021The Goldman Sachs GroupBoost Price TargetBuy$206.00 ➝ $228.00Low
i
5/6/2021Piper SandlerLower Price TargetOverweight$234.00 ➝ $231.00Low
i
5/5/2021Jefferies Financial GroupReiterated RatingHoldHigh
i
4/21/2021Piper SandlerReiterated RatingOverweight$208.00 ➝ $234.00High
i
4/18/2021SVB LeerinkReiterated RatingSellHigh
i
4/16/2021Needham & Company LLCReiterated RatingHoldHigh
i
4/15/2021Piper SandlerBoost Price TargetOverweight$208.00 ➝ $234.00Medium
i
3/15/2021Piper SandlerReiterated RatingOverweight$208.00Medium
i
3/1/2021Chardan CapitalBoost Price TargetPositive ➝ Buy$107.00 ➝ $182.00Low
i
Rating by Geulah Livshits at Chardan Capital
2/26/2021BarclaysBoost Price Target$169.00 ➝ $178.00Low
i
2/26/2021Brookline Capital ManagementBoost Price TargetBuy$180.00 ➝ $205.00Low
i
2/26/2021Bank of AmericaReiterated RatingSell$140.00High
i
Rating by Geoff Meacham at Bank of America Co.
2/25/2021Morgan StanleyLower Price TargetEqual Weight$215.00 ➝ $201.00High
i
2/18/2021Jefferies Financial GroupBoost Price Target$150.00 ➝ $180.00Medium
i
2/18/2021Morgan StanleyBoost Price TargetEqual Weight$150.00 ➝ $215.00High
i
2/17/2021Piper SandlerBoost Price Target$170.00 ➝ $208.00Low
i
2/1/2021OppenheimerBoost Price TargetOutperform$178.00 ➝ $206.00Low
i
2/1/2021Wells Fargo & CompanyBoost Price TargetOverweight ➝ Equal Weight$129.00 ➝ $145.00Low
i
2/1/2021SVB LeerinkBoost Price TargetUnderperform$69.00 ➝ $80.00Low
i
Rating by Mani Foroohar at SVB Leerink LLC
2/1/2021Bank of AmericaDowngradeNeutral ➝ Underperform$150.00Low
i
1/22/2021Bank of AmericaBoost Price TargetNeutral$130.00 ➝ $140.00Low
i
1/6/2021Piper SandlerReiterated RatingOverweight$166.00 ➝ $170.00N/A
i
12/21/2020SVB LeerinkBoost Price TargetPositive ➝ Underperform$60.00 ➝ $69.00High
i
Rating by Mani Foroohar at SVB Leerink LLC
12/21/2020OppenheimerBoost Price TargetOutperform$157.00 ➝ $178.00High
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
12/18/2020BarclaysBoost Price TargetOverweight$84.00 ➝ $169.00Low
i
12/16/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$100.00 ➝ $150.00N/A
i
12/15/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$90.00 ➝ $150.00High
i
Rating by Michael Yee at Jefferies Financial Group Inc.
12/11/2020The Goldman Sachs GroupReiterated RatingBuy$139.00Medium
i
12/9/2020Needham & Company LLCDowngradeBuy ➝ HoldHigh
i
Rating by Alan Carr at Needham & Company LLC
12/3/2020Bank of AmericaBoost Price Target$105.00 ➝ $150.00High
i
12/1/2020ArgusBoost Price TargetHold ➝ Buy$88.00 ➝ $200.00High
i
11/30/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$92.00 ➝ $129.00High
i
11/25/2020The Goldman Sachs GroupBoost Price Target$107.00 ➝ $139.00High
i
11/24/2020SVB LeerinkBoost Price TargetUnderperform$59.00 ➝ $60.00Low
i
Rating by Mani Foroohar at SVB Leerink LLC
11/23/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$92.00Low
i
11/17/2020Redburn PartnersInitiated CoverageSellMedium
i
11/17/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$109.00Medium
i
11/16/2020Chardan CapitalBoost Price TargetPositive ➝ Buy$93.00 ➝ $107.00High
i
Rating by Geulah Livshits at Chardan Capital
11/16/2020OppenheimerBoost Price TargetOutperform$108.00 ➝ $157.00High
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
11/16/2020Piper SandlerBoost Price TargetOverweight$136.00 ➝ $166.00High
i
11/11/2020ArgusBoost Price TargetBuy$80.00 ➝ $88.00High
i
11/11/2020Morgan StanleyBoost Price TargetOverweight$90.00 ➝ $100.00High
i
10/8/2020Chardan CapitalLower Price TargetBuy$95.00 ➝ $93.00Low
i
Rating by Geulah Livshits at Chardan Capital
9/24/2020SVB LeerinkReiterated RatingSell$41.00High
i
Rating by Mani Foroohar at SVB Leerink LLC
9/8/2020SVB LeerinkDowngradeMarket Perform ➝ Underperform$58.00 ➝ $41.00High
i
Rating by M. Foroohar at SVB Leerink LLC
8/12/2020Jefferies Financial GroupReiterated RatingBuy$90.00Medium
i
Rating by Michael Yee at Jefferies Financial Group Inc.
8/12/2020OppenheimerReiterated RatingBuy$108.00Medium
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
8/12/2020SVB LeerinkLower Price TargetMarket Perform$60.00 ➝ $58.00High
i
Rating by M. Foroohar at SVB Leerink LLC
8/12/2020Chardan CapitalReiterated RatingBuy$95.00High
i
Rating by Geulah Livshits at Chardan Capital
8/6/2020Chardan CapitalReiterated RatingBuy$95.00Low
i
Rating by Geulah Livshits at Chardan Capital
8/6/2020SVB LeerinkLower Price TargetMarket Perform$65.00 ➝ $60.00Medium
i
Rating by M. Foroohar at SVB Leerink LLC
8/6/2020JPMorgan Chase & Co.Reiterated RatingHoldMedium
i
8/5/2020Needham & Company LLCInitiated CoverageBuy$94.00Medium
i
Rating by Alan Carr at Needham & Company LLC
7/27/2020Chardan CapitalReiterated RatingBuy$95.00High
i
Rating by Geulah Livshits at Chardan Capital
7/27/2020SunTrust BanksInitiated CoverageBuy$120.00High
i
Rating by Welles Fitzpatrick at SunTrust Banks, Inc.
7/27/2020The Goldman Sachs GroupSet Price TargetBuy$105.00Medium
i
7/27/2020BMO Capital MarketsBoost Price TargetOutperform$94.00 ➝ $112.00Low
i
7/24/2020OppenheimerInitiated CoverageBuy$108.00High
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
7/23/2020SVB LeerinkInitiated CoverageMarket Perform$65.00High
i
Rating by M. Foroohar at SVB Leerink LLC
7/20/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$60.00 ➝ $89.00High
i
7/15/2020Needham & Company LLCInitiated CoverageBuy$94.00N/A
i
Rating by Alan Carr at Needham & Company LLC
7/15/2020OppenheimerInitiated CoverageBuy$108.00N/A
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
7/15/2020Piper SandlerBoost Price Target$100.00 ➝ $134.00High
i
7/15/2020Chardan CapitalBoost Price TargetBuy$84.00 ➝ $95.00N/A
i
Rating by Geulah Livshits at Chardan Capital
7/13/2020Brookline Capital ManagementReiterated RatingBuy$95.00High
i
Rating by L. Cann at Brookline Capital Management
7/13/2020Jefferies Financial GroupInitiated CoverageBuy$90.00N/A
i
6/30/2020ArgusInitiated CoverageBuy$80.00N/A
i
6/25/2020Chardan CapitalReiterated RatingBuy$84.00N/A
i
Rating by Geulah Livshits at Chardan Capital
6/12/2020Chardan CapitalReiterated RatingBuy$84.00N/A
i
Rating by Geulah Livshits at Chardan Capital
6/11/2020Needham & Company LLCReiterated RatingBuy$94.00N/A
i
Rating by Alan Carr at Needham & Company LLC
6/8/2020BarclaysInitiated CoverageOverweight$68.00N/A
i
6/3/2020Bank of AmericaLower Price Target$80.00 ➝ $75.00Medium
i
6/2/2020OppenheimerReiterated RatingBuy$108.00N/A
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
5/30/2020Chardan CapitalReiterated RatingBuy$52.00N/A
i
Rating by Gbola Amusa at Chardan Capital
5/20/2020Morgan StanleyBoost Price TargetOverweight$37.00 ➝ $90.00High
i
5/19/2020Bank of AmericaBoost Price TargetNeutral$70.00 ➝ $95.00N/A
i
5/19/2020BMO Capital MarketsBoost Price TargetOutperform$83.00 ➝ $112.00N/A
i
Rating by George Farmer at BMO Capital Markets
5/18/2020Needham & Company LLCInitiated CoverageBuy$94.00N/A
i
Rating by Alan Carr at Needham & Company LLC
5/18/2020OppenheimerBoost Price TargetOutperform$62.00 ➝ $108.00N/A
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
5/18/2020Piper SandlerBoost Price TargetOverweight$57.00 ➝ $102.00N/A
i
Rating by Edward Tenthoff at Piper Sandler
5/18/2020The Goldman Sachs GroupBoost Price TargetBuy$63.00 ➝ $105.00N/A
i
5/12/2020JPMorgan Chase & Co.Reiterated RatingBuy$60.00N/A
i
5/11/2020Roth CapitalBoost Price TargetBuy$41.00 ➝ $68.00N/A
i
5/8/2020OppenheimerBoost Price TargetOutperform$43.00 ➝ $62.00N/A
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
5/7/2020Needham & Company LLCBoost Price TargetBuy$35.00 ➝ $58.00N/A
i
5/1/2020Piper SandlerReiterated RatingBuy$57.00N/A
i
Rating by Edward Tenthoff at Piper Sandler
4/30/2020BMO Capital MarketsInitiated CoverageOutperform$83.00Medium
i
4/29/2020BMO Capital MarketsInitiated CoverageOutperformN/A
i
4/28/2020Chardan CapitalBoost Price TargetBuy$40.00 ➝ $52.00N/A
i
Rating by Geulah Livshits at Chardan Capital
4/21/2020OppenheimerInitiated CoverageBuy$43.00N/A
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
4/17/2020JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
4/17/2020Piper SandlerBoost Price Target$34.00 ➝ $57.00High
i
4/16/2020Roth CapitalBoost Price Target$33.00 ➝ $41.00High
i
Rating by Y. Rahimi at Roth Capital
4/15/2020Morgan StanleyBoost Price TargetOverweight$30.00 ➝ $37.00High
i
4/15/2020Chardan CapitalReiterated RatingBuy$40.00N/A
i
Rating by Geulah Livshits at Chardan Capital
4/15/2020OppenheimerBoost Price TargetOutperform$31.00 ➝ $43.00N/A
i
4/14/2020Piper SandlerReiterated RatingBuyN/A
i
Rating by Edward Tenthoff at Piper Sandler
3/30/2020Piper SandlerReiterated RatingBuy$34.00N/A
i
Rating by Edward Tenthoff at Piper Sandler
3/24/2020Needham & Company LLCReiterated RatingBuy$35.00N/A
i
3/16/2020Piper SandlerReiterated RatingBuy$32.00N/A
i
Rating by Edward Tenthoff at Piper Sandler
3/16/2020Chardan CapitalReiterated RatingBuy$40.00N/A
i
Rating by Geulah Livshits at Chardan Capital
3/5/2020Chardan CapitalReiterated RatingBuy$40.00N/A
i
Rating by Geulah Livshits at Chardan Capital
3/5/2020Bank of AmericaDowngradeBuy ➝ Neutral$32.00N/A
i
2/27/2020Roth CapitalBoost Price Target$24.00 ➝ $33.00High
i
Rating by Y. Rahimi at Roth Capital
2/26/2020Needham & Company LLCBoost Price TargetBuy$28.00 ➝ $35.00High
i
2/25/2020Piper SandlerReiterated RatingBuy$32.00N/A
i
Rating by Edward Tenthoff at Piper Sandler
2/25/2020Chardan CapitalReiterated RatingBuy$40.00N/A
i
Rating by Geulah Livshits at Chardan Capital
2/11/2020Chardan CapitalReiterated RatingBuy$40.00N/A
i
Rating by Geulah Livshits at Chardan Capital
1/22/2020Piper SandlerReiterated RatingBuy$32.00N/A
i
Rating by Edward Tenthoff at Piper Sandler
1/14/2020JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
1/10/2020Chardan CapitalReiterated RatingBuy$40.00N/A
i
Rating by Geulah Livshits at Chardan Capital
1/2/2020OppenheimerDowngradeOutperform$27.00Medium
i
1/2/2020Morgan StanleyInitiated CoverageOverweight$29.00N/A
i
Rating by Matthew Harrison at Morgan Stanley
1/2/2020BarclaysInitiated CoverageOverweight$20.00N/A
i
1/2/2020Bank of AmericaInitiated CoverageBuy$20.00N/A
i
1/2/2020JPMorgan Chase & Co.Initiated CoverageOverweight$22.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
1/2/2020Needham & Company LLCInitiated CoverageBuy$28.00N/A
i
Rating by Alan Carr at Needham & Company LLC
1/2/2020The Goldman Sachs GroupInitiated CoverageBuy$25.00N/A
i
1/2/2020Piper Jaffray CompaniesInitiated CoverageOverweight$24.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
12/3/2019Bank of AmericaReiterated RatingBuy$29.00High
i
12/3/2019Bank of AmericaInitiated CoverageBuy$29.00N/A
i
11/6/2019Needham & Company LLCReiterated RatingBuy$28.00N/A
i
Rating by Alan Carr at Needham & Company LLC
10/25/2019Roth CapitalReiterated RatingBuyLow
i
Rating by Y. Rahimi at Roth Capital
10/25/2019Roth CapitalInitiated CoverageBuy$24.00N/A
i
9/15/2019Chardan CapitalReiterated RatingBuyLow
i
Rating by Y. Livshits at Chardan Capital
9/15/2019JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
9/13/2019Needham & Company LLCSet Price TargetBuy$28.00N/A
i
Rating by Alan Carr at Needham & Company LLC
9/13/2019Chardan CapitalSet Price TargetBuy$40.00N/A
i
Rating by Gbola Amusa at Chardan Capital
9/13/2019Piper Jaffray CompaniesReiterated RatingBuy$30.00 ➝ $32.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
8/16/2019Piper Jaffray CompaniesSet Price TargetBuy$30.00N/A
i
Rating by Edward Tenthoff at Piper Jaffray Companies
8/12/2019Needham & Company LLCReiterated RatingBuy$28.00Medium
i
8/11/2019JPMorgan Chase & Co.Reiterated RatingBuy$24.00Medium
i
8/9/2019Morgan StanleySet Price TargetBuy$30.00N/A
i
Rating by Matthew Harrison at Morgan Stanley
6/2/2019Chardan CapitalReiterated RatingBuy$40.00High
i
5/29/2019OppenheimerBoost Price TargetOutperform$27.00 ➝ $31.00N/A
i
5/8/2019Piper Jaffray CompaniesBoost Price TargetOverweight$24.00 ➝ $30.00High
i
4/7/2019Chardan CapitalReiterated RatingBuyLow
i
Rating by G. Amusa at Chardan Capital
4/5/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$40.00High
i
3/19/2019OppenheimerReiterated RatingBuyHigh
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
1/10/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
i
1/2/2019OppenheimerInitiated CoverageOutperform$27.00High
i
1/2/2019Morgan StanleyInitiated CoverageOverweight ➝ Overweight$29.00Low
i
1/2/2019Needham & Company LLCInitiated CoverageBuy ➝ Buy$28.00High
i
1/2/2019BarclaysInitiated CoverageOverweight ➝ Overweight$20.00Medium
i
1/2/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$20.00Medium
i
1/2/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$22.00Medium
i
1/2/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$25.00Medium
i
1/2/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$24.00Medium
i
(Data available from 6/16/2016 forward)
Moderna logo
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $197.84
$193.20
$203.98

50 Day Range

MA: $174.81
$133.88
$219.57

52 Week Range

Now: $197.84
$54.21
$227.71

Volume

7,215,275 shs

Average Volume

11,071,096 shs

Market Capitalization

$79.44 billion

P/E Ratio

158.27

Dividend Yield

N/A

Beta

1.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Moderna?

The following Wall Street analysts have issued stock ratings on Moderna in the last twelve months: Argus, Bank of America Co., Barclays PLC, BMO Capital Markets, Brookline Capital Management, Chardan Capital, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Redburn Partners, SunTrust Banks, Inc., SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for MRNA.

What is the current price target for Moderna?

16 Wall Street analysts have set twelve-month price targets for Moderna in the last year. Their average twelve-month price target is $162.44, suggesting a possible downside of 17.9%. Piper Sandler has the highest price target set, predicting MRNA will reach $231.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $80.00 for Moderna in the next year.
View the latest price targets for MRNA.

What is the current consensus analyst rating for Moderna?

Moderna currently has 3 sell ratings, 6 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MRNA, but not buy more shares or sell existing shares.
View the latest ratings for MRNA.

What other companies compete with Moderna?

How do I contact Moderna's investor relations team?

Moderna's physical mailing address is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company's listed phone number is 617-714-6500 and its investor relations email address is [email protected] The official website for Moderna is www.modernatx.com.

Gain the Knowledge You Need to Successfully Trade Futures Markets
Our Technical Analysis Guide will give you the insight into today’s fast-moving markets. It’s designed to give you a head start in learning the basics of various TA tools and techniques.
pixel